NOVARTIND price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- NOVARTIND
- MB Code
- MBEQU3411
- ISIN
- INE234A01025
- BSE code
- 500672
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 90.55 Cr
- Net profit
- 25.25 Cr
- EPS
- 10.23
- YoY revenue
- +7.95%
Company documents
6 PDFs across 2 categories
Audited annual reports & financial statements
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for NOVARTIND
Novartis will divest its entire stake in Novartis India to a ChrysCapital-led consortium in a $159 million deal; an open offer has been p…
Novartis AG will sell its entire 70.68% stake in Novartis India for ₹1,445.89 crore to a consortium, triggering a mandatory open offer. S…
Novartis to sell majority stake in Novartis India in a ₹1,446 crore deal; consortium will pay public shareholders ₹860.64 per share, the …
Novartis India Ltd's promoter is selling its entire 70.68% stake, triggering an open offer at Rs 860.64 per share; the buyer will also re…
Novartis India shares jumped ~20% after ChrysCapital and two investors launched an open offer and promoters exited; stock rose past Rs 95…
Feb 20, 2026: Novartis India jumped 20% after Novartis AG agreed to sell 70.68% (1.74 crore shares) to a ChrysCapital-led group. A mandat…
Feb 20, 2026: A WaveRise-led buyout agreed to acquire nearly 71% of Novartis India for ₹14.46bn (~$159M), triggering a mandatory open off…
On Feb 20, 2026 Novartis AG agreed to sell 70.68% of Novartis India to a ChrysCapital‑led consortium; promoter exit, name to change withi…
Price returns
Historical performance
Technicals
Indicator consensus